Last November, a compounding pharmacist named Rachel in Austin told me something that stuck. She had three prescriptions for LL 37 come through in the same week, all for chronic infection adjunct use, and all three were at wildly different doses: 150 mcg subQ three times weekly, 750 mcg subQ five times weekly, and a nebulized protocol at 1,500 mcg daily. "None of them were wrong," she said. "That's the frustrating part for patients who want a single number."
She's right. LL 37 dosing is broad by nature. The peptide is compounded across multiple routes (subcutaneous injection, nebulization, topical cream or gel, intranasal spray), and the reference ranges reflect that flexibility. What follows is a consolidation of those ranges drawn from research literature and compounding practice. None of it substitutes for a prescriber's clinical judgment.
For those unfamiliar with the molecule itself, LL 37 is the only human cathelicidin antimicrobial peptide, a 37-amino-acid fragment cleaved from the precursor protein hCAP18. It is produced naturally by neutrophils, epithelial cells, and macrophages as part of the innate immune response. The therapeutic interest in exogenous LL 37 centers on its broad-spectrum antimicrobial activity, its capacity to disrupt bacterial biofilms, and its immunomodulatory effects. A 2013 review by Vandamme et al. in Cell Immunology detailed how LL 37 interacts with bacterial membranes, noting that the peptide inserts into lipid bilayers at concentrations as low as 1 to 5 micromolar in vitro, though translating bench concentrations to clinical dosing in humans is not a straightforward calculation.
That gap between in vitro data and clinical practice is exactly why reference ranges are wide and why prescriber judgment carries so much weight.
Subcutaneous Dosing: Where Most People Start
The most common route. Reference dosing for subcutaneous LL 37 in chronic infection adjunct contexts runs 100 to 1,000 mcg per administration, delivered 3 to 5 times per week. That's a ten-fold spread, which tells you how much context matters.
Initiation: Most protocols begin conservatively, 100 to 250 mcg per administration for the first 1 to 2 weeks. The reason is practical: LL 37 participates in biofilm disruption, and aggressive early dosing can trigger Herxheimer-like reactions (the die-off response that feels like getting worse before getting better). Starting low lets you gauge tolerance. A patient with a known high biofilm burden, such as someone with chronic Lyme co-infections confirmed through clinical workup, may need an even more cautious ramp. Some practitioners start at 50 to 100 mcg in those cases and extend the initiation window to three or four weeks.
Maintenance: After that initial window, titration to the 500 to 1,000 mcg range is typical if tolerance allows. The titration itself usually proceeds in 100 to 250 mcg increments, with each step held for several days before moving up. Jumping from 250 mcg directly to 1,000 mcg is not standard practice and invites unnecessary adverse reactions.
Frequency: Three to five times weekly is the common cadence. Some protocols call for daily dosing during limited windows, but that's the exception rather than the rule. A 2014 study published in PLOS ONE by Krasnodembskaya et al. explored LL 37's effects on bacterial clearance in a pneumonia model and noted that repeated dosing was more effective than single large administrations, which supports the rationale for spreading doses across the week rather than loading everything into one or two sessions.
Here's the thing about subcutaneous LL 37 that differentiates it from something like BPC-157: the dose-response relationship is less linear and more context-dependent. A patient dealing with chronic Lyme co-infections and a patient using it as a general immune modulator may land in completely different parts of that range. The prescriber's clinical picture drives the number. Body weight plays a role as well, but it is not the primary variable. Infection type, biofilm status, concurrent medications, and immune function all carry more weight in dose selection than the number on the scale.
Nebulized Protocols for Respiratory Applications
Nebulized LL 37 is a smaller niche, but it's growing, particularly in chronic respiratory infection contexts. Reference dosing delivers 500 to 2,000 mcg per nebulization treatment, anywhere from daily to several times weekly.
The boring truth about nebulized LL 37 is that the formulation matters more than most patients realize. It's not just peptide-in-saline. The carrier, pH, and osmolarity all need to be calibrated for safe airway delivery. The target pH range for inhaled peptide solutions is typically 4.5 to 7.5, and osmolarity should approximate isotonic conditions to avoid bronchospasm or mucosal irritation. Not every compounding pharmacy has the capability to prepare this correctly, and you should ask directly whether they do rather than assuming.
Equipment is the other variable. Standard household nebulizers (the kind you'd use for albuterol) may not atomize peptide solutions effectively. Mesh nebulizers tend to produce finer particle sizes (1 to 5 microns) suitable for lower airway deposition, while jet nebulizers may waste a significant portion of the peptide in the device reservoir. The dispensing pharmacy should specify which nebulizer type works with their formulation. If they don't offer that guidance unprompted, that's a yellow flag.
It is also worth noting that a 2012 study by Beaumont et al. in Peptides found that LL 37 retained antimicrobial activity against Pseudomonas aeruginosa biofilms in an airway model, which is part of the rationale for nebulized use in patients with chronic respiratory colonization. But "retained activity in a model" and "proven clinical efficacy in human lungs" are not the same sentence. The evidence base is preclinical and observational, not trial-validated for this route.
Topical and Intranasal: The Less Common Routes
Topical (chronic wound applications): LL 37 cream or gel preparations typically run 50 to 100 mcg per mL of base. Application is once or twice daily to a cleaned wound surface. Research by Heilborn et al. published in the Journal of Investigative Dermatology (2003) identified reduced LL 37 expression in chronic ulcers compared to normally healing acute wounds, which formed part of the biological rationale for topical supplementation. An important note that sometimes gets lost in peptide enthusiasm: topical LL 37 is an adjunct to standard wound care, not a substitute for it. Debridement, moisture management, addressing underlying vascular or metabolic issues, all of that stays primary. If the wound bed is not properly prepared, no amount of topical peptide will compensate.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →For practical application, patients should clean the wound per their wound care provider's instructions, apply a thin layer of the LL 37 formulation, and cover with an appropriate dressing. The peptide should not be mixed with other topical agents unless the prescriber specifically approves the combination, as pH interactions or preservative conflicts can degrade the peptide before it reaches the tissue.
Intranasal (chronic sinusitis contexts): Delivered as a spray, usually 100 to 500 mcg per actuation, once or twice daily. Formulation requires appropriate pH and osmolarity. The dispensing pharmacy sets those parameters. Patients using intranasal LL 37 should clear the nasal passages with saline irrigation first to remove mucus and debris, then administer the spray. Applying the peptide into a congested, mucus-coated nasal cavity reduces mucosal contact and wastes product.
Timing, Cycling, and How Long to Run a Course
There's no strong consensus on optimal time of day for LL 37. Most protocols just aim for consistency. One practical observation: if you're experiencing Herxheimer-like reactions, morning administration lets symptoms develop and resolve before bedtime. That's preference, not pharmacology.
Some practitioners note that LL 37 may interact with the body's circadian immune rhythms, given that cathelicidin expression follows a diurnal pattern influenced by vitamin D metabolism. A 2009 study by Liu et al. in Science established the vitamin D-cathelicidin axis in innate immunity. While this does not directly dictate dosing time, patients with low vitamin D levels should address that deficiency, as suboptimal vitamin D status may blunt the downstream effects that exogenous LL 37 is intended to support.
Cycle length is where prescriber philosophy shows up most. The common framework is a 6 to 12 week initial assessment course followed by reassessment. Some protocols extend beyond that window based on clinical response. Others use intermittent on/off cycling, such as 8 weeks on and 4 weeks off. Neither approach has formal validation in controlled trials, which is an honest limitation of where the evidence stands right now.
Long-term continuous use is an open question. The peptide community tends to run longer courses than published research supports with confidence. The concern is not so much toxicity at standard doses but rather the absence of long-term safety data specific to exogenous LL 37 administration. Your prescriber should be monitoring relevant markers, including inflammatory markers, liver function, and kidney function, particularly during extended courses.
Reconstitution, Storage, and the Shelf-Life Problem
LL 37 is typically supplied lyophilized (freeze-dried) and reconstituted with bacteriostatic water per pharmacy guidance. Here's where LL 37 differs from more stable peptides: it's sensitive to proteolytic degradation. Translation: it breaks down faster once reconstituted.
Reconstituted solution goes in the refrigerator at 2 to 8 degrees Celsius. The beyond-use date set by the dispensing pharmacy may be shorter than what you're used to with other peptides, often in the range of 14 to 28 days rather than the 30 to 60 days common with more stable compounds. Respect it. A degraded LL 37 solution isn't dangerous in the way a contaminated one would be, but you're injecting expensive water at that point.
Handling specifics matter as well. Do not shake the vial vigorously during reconstitution. LL 37 is a relatively small peptide (4.5 kDa), but aggressive agitation can cause aggregation at the air-liquid interface. Gentle swirling is the standard recommendation. When drawing from the vial, use a fresh needle each time to minimize contamination risk, and avoid touching the rubber stopper with your fingers after wiping it with an alcohol swab.
Topical and nebulized formulations carry their own storage requirements. Follow the pharmacy's instructions, not internet forum advice.
When Dosing Adjustments Make Sense
This is a prescriber call, but the common triggers are predictable:
Herxheimer-like reactions during initiation: The response is temporary dose reduction or a longer low-dose ramp before titrating up. Pushing through significant die-off reactions is not a badge of honor; it's unnecessary suffering. Symptoms to watch for include increased fatigue, joint pain, headache, low-grade fever, and worsening of baseline symptoms. If reactions are severe, skipping a dose or two and then resuming at a lower amount is reasonable.
Injection site reactions: Lower per-administration volume, more aggressive site rotation (cycling through abdominal subcutaneous tissue, thigh, and upper outer arm), and a conversation with the pharmacy about formulation variables. Occasionally, the issue is the reconstitution volume itself. Some patients tolerate the same microgram dose better when it is diluted into a slightly larger injection volume, reducing the local concentration of peptide at the injection site.
Insufficient response after a full assessment course at maintenance dosing: The instinct is to escalate the dose. The better instinct is to reassess the clinical picture. Is the diagnosis right? Are there co-factors being missed? Is there an underlying immune deficiency limiting the peptide's effect? Dose escalation without context is guessing louder.
Changes in concurrent medication: Starting or stopping antibiotics, immunosuppressants, or corticosteroids during an LL 37 course may warrant dose adjustment. LL 37 and conventional antibiotics may have additive effects against certain organisms, which is sometimes desirable and sometimes a reason to lower the peptide dose. Corticosteroids suppress cathelicidin expression naturally, so adding exogenous LL 37 while on steroids introduces a variable that the prescriber needs to account for.
The Autoimmune Caveat You Shouldn't Skip
LL 37 has a documented signal in psoriasis and potentially other autoimmune conditions. This isn't a theoretical concern. In psoriatic skin, LL 37 complexes with self-DNA to activate plasmacytoid dendritic cells, driving the inflammatory cascade. Lande et al. published this mechanism in Nature (2007), demonstrating that LL 37 converts inert self-DNA into a trigger for autoimmune inflammation via Toll-like receptor 9 activation. If you have active autoimmune disease, the question isn't what dose is right. The question is whether LL 37 is appropriate at any dose. That conversation belongs with your prescriber, and it should happen before your first injection, not after a flare.
The concern extends beyond psoriasis. There is preliminary evidence linking cathelicidin dysregulation to lupus and rosacea as well. Patients with a personal or strong family history of autoimmune conditions should disclose that information completely and discuss it explicitly before starting LL 37 at any dose or by any route.
Separately: LL 37 in chronic infection contexts is researched as an adjunct, not a replacement for conventional antibiotic management. If you have an active infection requiring antibiotics, take the antibiotics.
What This Article Isn't
A protocol. A prescription. Medical advice. It's a consolidation of commonly referenced ranges from published research and compounding pharmacy practice. Your dose is between you, your prescriber, and the pharmacy filling the script.
Frequently Asked Questions
What is a typical starting dose for subcutaneous LL 37?
100 to 250 mcg per administration, 3 to 5 times per week, for the first 1 to 2 weeks before titrating upward to maintenance dosing. Patients with known high biofilm burden may start even lower, at 50 to 100 mcg.
Can LL 37 be nebulized at home?
Yes, but it requires specifically formulated solution from a compounding pharmacy with nebulization capability, plus appropriate nebulizer equipment (typically a mesh nebulizer). This is not a DIY formulation project, and the pharmacy should specify compatible device types.
How often should I rotate injection sites?
Every administration at a different site. A standard rotation cycles through abdominal subcutaneous tissue, thigh, and upper outer arm. Keeping a simple log (even a note on your phone) prevents accidentally hitting the same site on consecutive days.
Do I need to cycle off LL 37?
Cycle structure is a prescriber decision. A 6 to 12 week assessment course followed by reassessment is the most common framework. Continuous extended use lacks formal validation, and periodic reassessment of clinical response and lab markers is appropriate.
Can I take LL 37 alongside antibiotics?
The combination is described in some protocols and may have additive antimicrobial effects against certain organisms. It's a prescriber decision based on your specific clinical situation, the antibiotic class involved, and the target pathogen.
How should I store reconstituted LL 37?
Refrigerated at 2 to 8 degrees Celsius, and used within the beyond-use date set by the dispensing pharmacy. LL 37 degrades faster than many peptides once reconstituted, so the window may be shorter than you expect, often 14 to 28 days.
Is LL 37 safe for people with autoimmune conditions?
There is a documented autoimmune signal, particularly in psoriasis, with additional preliminary concerns in lupus and rosacea. Active autoimmune disease warrants a careful risk-benefit discussion with your prescriber before starting any dose. This conversation should happen before the first administration, not in response to a flare.
Related Reading
- LL 37 Hub
- LL 37 for Chronic Infection Protocols
- Thymosin Alpha 1 Hub
- Best Peptides for Healing and Recovery
Compliance Footer
LL 37 is not approved by the FDA for the prevention, mitigation, treatment, or cure of any disease. Compounded LL 37 is prepared by licensed compounding pharmacies for individual patients under a valid prescription from a licensed prescriber. Information on this page is educational and is not medical advice. Individual results vary.